This Startup Lets Paralyzed People Use Computers–Without A Chip In Their Head
Startup Cognixion, which has developed a noninvasive brain-computer interface, has begun a clinical trial for patients with ...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
MassDevice2h
Cognixion launches trial of BCI device paired with AI application for people with ALS
Cognixion announced today that it launched a clinical trial evaluating its integrated, wearable augmented reality and BCI ...
Cognixion Launches Clinical Trial for Late-Stage ALS to Deliver Conversation Level Communication with Adaptive AI-Driven Brain-Computer Interface
The study will measure the impact of Cognixion's novel combination of BCI, AI and AR technology on the ability of amyotrophic ...
Devdiscourse6h
AKGsOVIHAMS: Revolutionizing ALS Treatment with Integrative Medicine
AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...
Fierce Biotech6d
Denali's ALS drug fails to redeem itself, missing key biomarker in trial extension
Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...
Repurposed amyotrophic lateral sclerosis drug becomes imaging probe to help diagnose neurodegeneration
Positron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative ...
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.